Clinical Trials

Below is a listing of Clinical Trials supported by the US National Cancer Institute (NCI) for breast cancer that accept men, which I update weekly.

To the right you see a button that allows you to search the trial listings of BreastCancerTrials.org for trials focused on metastatic disease and a link that allows you to do a search on that site for all the trials that accept men.

The list below was compiled by searching the NCI Clinical Trials data base for trials focused on breast cancer as the lead disease, a manually curated piece of information that the team at the NCI provides, and looking for trials that allow men to be enrolled. If you see a trial that is of interest to you, please click through to the NCI’s webpage using the link provided, and find a site offering it near you and then reach out to learn more about whether you are eligible.

This listing contains 2 trials, and was last updated on 2022-07-25

————–

Acupuncture for the Prevention of Nerve Pain in Patients with Breast Cancer Undergoing Taxane Chemotherapy

Acupuncture for Preventing Progression of Taxane-Induced Peripheral Neuropathy (ATP): A Phase II Randomized, Placebo Controlled Trial

Phase II

This phase II trial tests the effect of acupuncture on nerve pain (peripheral neuropathy) caused by taxane chemotherapy in patients with breast cancer. Peripheral neuropathy is a common, potentially painful, debilitating, and dose-limiting side effect from many chemotherapy drugs, including taxane. There currently is no effective treatment or preventative measure for peripheral neuropathy. Acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body. Real acupuncture may help prevent peripheral neuropathy pain from getting worse when compared to placebo (sham) acupuncture in patients with breast cancer undergoing chemotherapy.

Start date: 2022-07-11.

This trial is being offered at including in the following states:

NJ | NY

For more information including sites offering the trial visit this NCI page: NCI-2022-05881

Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer

Phase 1 Study of Adoptive T Cell Therapy following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/ Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer

Phase I

This trial includes Her-2 positive tumors, which are very rare among men with breast cancer. Please check your eligibility.

This phase I trial tests the safety, side effects, and best dose of adoptive T-cell therapy following HER2-pulsed dendritic cell vaccine, pepinemab, and trastuzumab in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic). The adoptive T cell therapy has the potential to enhance antitumor immunity and efficacy for the treatment of cancer. It’s a type of immunotherapy where T cells (a type of immune cells) are given to patients to help the body fight cancer. Dendritic cell vaccine is made from the blood cells collected from a procedure called leukapheresis. Dendritic cells are immune cells that can tell the immune system to fight infection. Pepinemab and trastuzumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Giving adoptive T-cell therapy following HER2-pulsed dendritic cell vaccine, pepinemab, and trastuzumab may work better in treating patients with HER2 positive breast cancer.

Start date: 2022-05-05.

This trial is being offered at including in the following states:

FL

For more information including sites offering the trial visit this NCI page: NCI-2022-04424


The search strategy used to identify these trials was updated on March 14th, 2021 as described in a recent post.